Cervical cancer is the fourth most common cancer among females. The uncontrolled growth of cells in the cervical region of a uterus is called cervical cancer. Strains of Human Papillomavirus (HPV), generally a sexually transmitted antigen, is the general cause of cervical cancer. The disease begins when healthy cells acquire a mutation, leading to the uncontrolled growth of cells. Cervical cancer is common in low and middle-income countries. According to the World Health Organization (WHO), cancer is the second leading cause of death globally. In 2015, cancer was responsible for 8.8 million deaths.
The increasing prevalence of cervical cancer and growing awareness pertaining to cervical cancer among women have been driving the cervical cancer treatment market growth. According to World Health Organization (WHO), cervical cancer accounted for 3.7% of all cancers worldwide in 2015. In 2012, 528,000 women were diagnosed with cervical cancer around the globe. Unprotected sexual contact and multiple pregnancies increase the chances of cervical cancer. Moreover, the growing trend of consuming alcohol and tobacco products at a young age is also adding to the cervical cancer patient pool.
The high cost of medical devices used in cervical cancer treatment and the high expertise required for treatment are hindering market growth. Moreover, the side effects associated with medicines & therapies used in treatment are also challenging market growth to an extent.
The availability of a limited number of treatments and medicines creates an opportunity for key players to introduce more cost-effective methods to cure cervical cancer. Government and private players are investing in research and development to improve cancer treatment methods, which is expected to fuel market growth in near future.
The global cervical cancer treatment market was valued at USD 6,994.3 million in 2018 and is anticipated to expand at a CAGR of 5.2% during the forecast period to attain a value of USD 11,369.5 million by 2026.
To learn more about key trends >> Download Sample Report
The cervical cancer treatment market has been segmented by type, treatment, end user and region.
By type, the cervical cancer treatment market has been segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. The squamous cell carcinomas segment is expected to account for a significant market share, owing to the growing awareness among masses.
By treatment, the market has been segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others. Among these, the surgery segment is anticipated to lead the market during the forecast period, owing to availability of skilled doctors.
Based on end user, the cervical cancer treatment market has been segmented into hospitals, cancer care centers, research institute, and others. The hospital segment is expected to hold a major market share during the forecast period.
Globally, the cervical cancer treatment market has been segmented into four regions; North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
To understand geography trends >> Download Sample Report
North America is expected to account for a sizeable market share during the forecast period, owing to the region’s large patient pool. According to the National Cancer Institute, in 2015, an estimated 257,524 women were living with cervical cancer in the United States. The region also has advanced technologies for cancer treatment, which is anticipated to support market growth.
Europe holds a notable share of the cervical cancer treatment market, owing to technological advancements and the growing incidences of cervical cancer in the region. Additionally, the favorable reimbursement scenario and presence of eminent global players in the region also drive market growth to an extent.
Asia Pacific is projected to register the fastest growth in the cervical cancer treatment market, owing to the growing geriatric population and increasing prevalence of cervical cancer in the region. According to the World Health Organization (WHO), of the total cancer mortality in India, 20.7% is attributed to cervical and uterine cancer. Medical facilities in the region are not technically advanced, which presents an opportunity for market players to introduce advanced equipment and treatment options.
The LAMEA region is expected to exhibit sluggish market growth during the forecast period, owing to underdeveloped economies and lack of medical facilities. However, the region has significant growth potential, as the region’s massive cervical cancer patient pool presents an opportunity to cater treatment alternatives. As per World Health Organization (WHO) data, the cancer mortality of females in South Africa is 20,600 of which, 16.9% is attributed to cervical and uterine cancer.
Some of the key players in the global cervical cancer therapeutics market are Novartis AG, Genentech USA, AstraZeneca plc, Eli Lilly and Company, Pfizer, Inc., Allergan, Bristol-Myers Squibb Company, Actavis Pharma Company, Seimens Healthcare, QIAGEN, and GlaxoSmithKline plc.
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Type, Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy)|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Novartis AG, Genentech USA, AstraZeneca plc, Eli Lilly and Company, Pfizer, Inc., Allergan, Bristol-Myers Squibb Company, Actavis Pharma Company, Seimens Healthcare, QIAGEN, and GlaxoSmithKline plc.|
|Key Market Opportunities||Rising Demand For Cervical Cancer Treatment In Healthcare It Industry|